Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.
Seoyoung C KimSebastian SchneeweissDong Wook KimElisabetta PatornoPublished in: Diabetes, obesity & metabolism (2021)
The overall use of antiobesity medications remained low over the past 15 years and phentermine was the preferred antiobesity agent. Although the use of potentially safer antiobesity agents, for example, liraglutide 3.0 mg, has increased in recent years, phentermine remained the most frequently prescribed agent among middle-aged adults with a moderate burden of comorbidities.